8.92
0.09 (1.08%)
| Penutupan Terdahulu | 8.82 |
| Buka | 8.80 |
| Jumlah Dagangan | 575,767 |
| Purata Dagangan (3B) | 1,863,554 |
| Modal Pasaran | 1,508,560,256 |
| Harga / Jualan (P/S) | 4.32 |
| Harga / Buku (P/B) | 1.52 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2026 |
| Margin Operasi (TTM) | -4,568.83% |
| EPS Cair (TTM) | -4.23 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -94.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 9.21% |
| Nisbah Semasa (MRQ) | 6.79 |
| Aliran Tunai Operasi (OCF TTM) | -415.08 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -310.09 M |
| Pulangan Atas Aset (ROA TTM) | -23.52% |
| Pulangan Atas Ekuiti (ROE TTM) | -44.59% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Vir Biotechnology, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.50 |
|
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 10.57% |
| % Dimiliki oleh Institusi | 79.54% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Arch Venture Management, Llc | 31 Mar 2026 | 12,916,663 |
| Sb Investment Advisers (Uk) Ltd | 31 Mar 2026 | 10,948,093 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |